Browse > Article
http://dx.doi.org/10.3340/jkns.2014.55.2.69

Effect of Discontinuation of Anticoagulation in Patients with Intracranial Hemorrhage at High Thromboembolic Risk  

Jung, Hwan-Su (Department of Neurosurgery, Yeungnam University Medical Center, Yeungnam University School of Medicine)
Jeon, Ik-Chan (Department of Neurosurgery, Yeungnam University Medical Center, Yeungnam University School of Medicine)
Chang, Chul-Hoon (Department of Neurosurgery, Yeungnam University Medical Center, Yeungnam University School of Medicine)
Jung, Young-Jin (Department of Neurosurgery, Yeungnam University Medical Center, Yeungnam University School of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.55, no.2, 2014 , pp. 69-72 More about this Journal
Abstract
Objective : There was no abundance of data on the use of anticoagulant in patients with previous high risk of thromboembolic conditions under a newly developed intracranial hemorrhage in Korean society. The purpose of this study was to evaluate the safety of discontinuance and suggest the proper time period for discontinuance of anticoagulant among these patients. Methods : We reviewed the medical records of 19 patients who took anticoagulant because of thromboembolic problems and were admitted to our department with newly developed anticoagulation associated intracranial hemorrhage (AAICH), and stopped taking medicine due to concern of rebleeding from January 2008 to December 2012. Analysis of the incidence of thromboembolic complications and proper withdrawal time of anticoagulant was performed using the Kaplan-Meier method. Results : Our patients showed high risk for thromboembolic complication. The $CHA_2DS_2$-VASc score ranged from two to five. Thromboembolic complication occurred in eight (42.1%) out of 19 patients without restarting anticoagulant since the initial hemorrhage. Among them, three patients (37.5%) died from direct thromboembolic complications. Mean time to outbreak of thromboembolic complication was $21.38{\pm}14.89$ days (range, 8-56 days). The probability of thromboembolic complications at 7, 14, and 30 days since cessation of anticoagulation was 0.00, 10.53, and 38.49%, respectively. Conclusion : Short term discontinuance of anticoagulant within seven days in patients with AAICH who are at high embolic risk ($CHA_2DS_2$-VASc score >2) appears to be relatively safe in Korean people. However, prolonged cessation (more than seven days) may result in increased incidence of catastrophic thromboembolic complications.
Keywords
Anticoagulation; Intracerebral hemorrhage; Thromboembolic complication;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ : Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation. Chest 137 : 263-272, 2010   DOI
2 Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY : The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1 : a nationwide cohort study. Thromb Haemost 107 : 1172-1179, 2012   DOI
3 Tinker JH, Tarhan S : Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 239 : 738-739, 1978   DOI
4 Wijdicks EF, Schievink WI, Brown RD, Mullany CJ : The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 42 : 769-773, 1998   DOI
5 Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 : 2719-2747, 2012   DOI   ScienceOn
6 Hacke W : The dilemma of reinstituting anticoagulation for patients with cardioembolic sources and intracranial hemorrhage : how wide is the strait between Skylla and Karybdis? Arch Neurol 57 : 1682-1684, 2000   DOI
7 Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K : Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 44 : 438-442; discussion 443, 1995   DOI   ScienceOn
8 Ananthasubramaniam K, Beattie JN, Rosman HS, Jayam V, Borzak S : How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 119 : 478-484, 2001   DOI
9 Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. : Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults : 2007 Update : A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group : The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 116 : e391-e413, 2007   DOI
10 Butler AC, Tait RC : Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage : a 2-year follow-up. Br J Haematol 103 : 1064-1066, 1998   DOI
11 Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. : Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 120 : 700-705, 2007   DOI